Skip to main content

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Recruiting · Phase 2 · NCT06548542

Conditions: Crohn's Disease

At a glance

Research payments reported, 2025
$3.1M
U.S. investigators named
55
Sites paid
48
Planned or actual enrollment
590

About the trial

Sponsor
AbbVie
Tested
Risankizumab (drug), Lutikizumab (drug), Trosunilimab (drug), Risankizumab (drug), Trosunilimab (drug), ABBV-8736 (drug)
Dates
Started 2024-09-04; completion 2030-01
Results posted
Not yet

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD. The medicines assessed in this study are risankizumab, trosunilimab, lutikizumab, and ABBV-8736. When participants join the study, they will be randomized into available study treatment groups. Adul…

From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $3.1M in research payments for this study in 2025 (328 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Tyler Research Institute LLC $492,443
  • Caprock Gastro Research LLC $235,139
  • Texas Digestive Disease Cons PLLC $212,189
  • The Ohio State University $176,179
  • The Feinstein Institute for Medical Research $141,789
  • Bvl Clinical Research LLC $131,077
  • Gi Associates Research LLC $126,576
  • East View Medical Research LLC $120,870
  • University of California Davis Medical Center, CA $115,720
  • Endoscopic Research Inc $114,449
  • Nature Coast Clinical Research $108,002
  • Osf Heart of Mary Medical Center, IL $99,729
  • Lucida Clinical Trials $77,227
  • Mgg Group Co Inc DBA Chevy Chase Clinical Research $71,431
  • Yale University $60,837
  • Mayo Clinic Rochester $60,572
  • University of Cincinnati $55,321
  • Springfield Clinic LLP $49,926
  • The Methodist Hospital Research $48,148
  • Osf Little Company of Mary Medical Center, IL $45,692
  • Care Access Research LLC $45,586
  • Univ of Florida Board of Trustees $40,686
  • Univ of Kentucky Research Found $39,416
  • Sun Research Institute LLC $38,917
  • Benaroya Research Institute $38,473
  • The University of Chicago $37,700
  • Regents of the Univ of California $34,926
  • A Positive Research Inc $33,495
  • Washington Univ in St Louis $31,133
  • Pennsylvania State University $29,850
  • Adventhealth Carrollwood, FL $28,800
  • Hillcrest Medical Research LLC $22,023
  • Peak Gastroenterology Associates $17,685
  • Wake Forest University $17,000
  • Novum Research LLC $16,900
  • Gastroenterology Associates Of $16,457
  • Nuvance Health $16,346
  • Las Vegas Medical Research LLC $16,157
  • Treasure Valley Medical Research $16,129
  • Gut PC $12,199
  • New York University $11,416
  • East Tennessee Research Institute $9,126
  • Clinical Associates in Research $9,025
  • Velocity Clinical Research Inc $6,815
  • UCSF Langley Porter Psychiatric Hospital and Clinics, CA $5,023
  • Gastro Assc of Orangeburg PA $4,469
  • $4,097
  • Advanced Research Institute Inc $3,449
  • Icahn School of Med at Mt Sinai $750

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.